Thorium-229 is a unique case in nuclear physics: it presents a metastable first excited state 229m Th, just a few electronvolts above the nuclear ground state. This so-called isomer is accessible by VUV lasers, which allows transferring the amazing precision of atomic laser spectroscopy to nuclear physics. Being able to manipulate the 229 Th nuclear states at will opens up a multitude of prospects, from studies of the fundamental interactions in physics to applications as a compact and robust nuclear clock. However, direct optical excitation of the isomer or its radiative decay back to the ground state has not yet been observed, and a series of key nuclear structure parameters such as the exact energies and half-lives of the low-lying nuclear levels of 229 Th are yet unknown. Here we present the first active optical pumping into 229m Th. Our scheme employs narrow-band 29 keV synchrotron radiation to resonantly excite the second excited state, which then predominantly decays into the isomer. We determine the resonance energy with 0.07 eV accuracy, measure a half-life of 82.2 ps, an excitation linewidth of 1.70 neV, and extract the branching ratio of the second excited state into the ground and isomeric state respectively. These measurements allow us to re-evaluate gamma spectroscopy data that have been collected over 40 years.

Tissue factor (TF), the trigger protein of the extrinsic blood coagulation cascade, is abundantly expressed in various cancers including gastric cancer. Anti‐TF monoclonal antibodies (mAbs) capable of targeting cancers have been successfully applied to armed antibodies such as antibody‐drug conjugates (ADCs) and molecular imaging probes. We prepared an anti‐TF mAb, clone 1084, labeled with astatine‐211 (211At), as a promising alpha emitter for cancer treatment. Alpha particles are characterized by high linear energy transfer and a range of 50‐100 µm in tissue. Therefore, selective and efficient tumor accumulation of alpha emitters results in potent antitumor activities against cancer cells with minor effects on normal cells adjacent to the tumor. Although the 211At‐conjugated clone 1084 (211At‐anti‐TF mAb) was disrupted by an 211At‐induced radiochemical reaction, we demonstrated that astatinated anti‐TF mAbs eluted in 0.6% or 1.2% sodium ascorbate (SA) solution were protected from antibody denaturation, which contributed to the maintenance of cellular binding activities and cytocidal effects of this immunoconjugate. Although body weight loss was observed in mice administered a 1.2% SA solution, the loss was transient and the radioprotectant seemed to be tolerable in vivo. In a high TF–expressing gastric cancer xenograft model, 211At‐anti‐TF mAb in 1.2% SA exerted a significantly greater antitumor effect than nonprotected 211At‐anti‐TF mAb. Moreover, the antitumor activities of the protected immunoconjugate in gastric cancer xenograft models were dependent on the level of TF in cancer cells. These findings suggest the clinical availability of the radioprotectant and applicability of clone 1084 to 211At‐radioimmunotherapy.

A facile synthesis of an 211At-labeled immunoconjugate for α-emission therapy was achieved based on a one-pot three-component double click method.